Home › Companies › NORTHWEST BIOTHERAPEUTICS INC. › 2023-2024
At NORTHWEST BIOTHERAPEUTICS INC.'s shareholder meeting held June 29, 2024, in the 2023-2024 proxy season, 85 asset managers reported how they voted on 3 ballot items in their SEC Form N-PX filings, covering 95 separate fund positions. On the most widely held item on that ballot — To approve on an advisory basis the Company's executive compensation — FOR was 87% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: NORTHWEST BIOTHERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on July 3, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and NORTHWEST BIOTHERAPEUTICS INC.’s Form 8-K, filed July 3, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 29, 2024: 6 items on NORTHWEST BIOTHERAPEUTICS INC.’s Form 8-K, filed July 3, 2024: 6 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024 2025-2026
Explore NORTHWEST BIOTHERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are NORTHWEST BIOTHERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed July 3, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Dr. Alton L. Boynton | 718,437,871 | -- | -- | 45,523,475 | 197,729,565 | 94% | Not verified | — |
| Elect Director: Ambassador J. Cofer Black | 710,592,953 | -- | -- | 53,368,393 | 197,729,565 | 93% | Not verified | — |
| 2. Ratification of Appointment of Registered Public Accounting Firm. The common and preferred stockholders, voting as a single class, ratified the appointment of Cherry Bekaert LLP as the Company's independent registered public accounting firm for the fiscal y | 884,823,568 | 69,395,476 | 7,471,867 | -- | 0 | 93% | Not verified | — |
| 3. Ratification Of The Same Option Awards That Were Made In 2020 To The Named Executive Officers And For Which The Stockholders Already Voted In Favor In An Advisory Vote At The 2021 Annual Meeting And In A Ratification Vote At The 2022 Annual Meeting. The com | 667,076,388 | 89,877,155 | 7,007,803 | -- | 197,729,565 | 88% | Not verified | — |
| 4. Ratification Of The Same Option Awards That Were Made In 2020 To The Non-Executive Directors On The Board Of Directors, And That Were Previously Reported And Previously Approved By Stockholders At The 2022 Annual Meeting. The common and preferred stockholde | 661,462,536 | 89,760,789 | 12,738,021 | -- | 197,729,565 | 88% | Not verified | — |
| 5. Advisory Vote on 2023 Executive Compensation. The common and preferred stockholders, voting as a single class, approved the Company's 2023 executive compensation. the approval | 659,480,960 | 95,353,125 | 9,127,261 | -- | 197,729,565 | 87% | Not verified | — |
Source: NORTHWEST BIOTHERAPEUTICS INC., Form 8-K, filed with the SEC on July 3, 2024 — read the filing on EDGAR.
Each item below shows how the 85 asset managers that disclosed a NORTHWEST BIOTHERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 2 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: To ratify the same option awards that were made in 2020 to the non-executive Directors on the Board of Directors, and that were previously reported and previously approved by stockholders at the 2022 Annual Meeting
NORTHWEST BIOTHERAPEUTICS INC.’s own tally for this item (“4. Ratification Of The Same Option Awards That Were Made In 2020 To The Non-Executive Directors On The Board Of Directors, And That Were Previously Reported And Previously Approved By Stockholders At The 2022 Annual Meet”): 661,462,536 for, 89,760,789 against, per its Form 8-K filed July 3, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 2 asset managers below reported 6,000 for, 2,100 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Berkeley Capital Partners, LLC | 6,000 | 0 | 0 | 0 | For |
| Janney Montgomery Scott LLC | 0 | 2,100 | 0 | 0 | Against |
Combines 9 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: To approve on an advisory basis the Company's executive compensation
NORTHWEST BIOTHERAPEUTICS INC.’s own tally for this item (“5. Advisory Vote on 2023 Executive Compensation. The common and preferred stockholders, voting as a single class, approved the Company's 2023 executive compensation. the approval”): 659,480,960 for, 95,353,125 against, per its Form 8-K filed July 3, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 84 asset managers below reported 4,301,202 for, 12,960 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Badgley Phelps Wealth Managers, LLC | 614,820 | 0 | 0 | 0 | For |
| BNY Mellon | 583,701 | 0 | 0 | 0 | For |
| HighTower Advisors, LLC | 411,161 | 0 | 0 | 0 | For |
| Corient Private Wealth LLC | 280,741 | 0 | 0 | 0 | For |
| OPPENHEIMER & CO INC | 266,280 | 0 | 0 | 0 | For |
| Moloney Securities Asset Management, LLC | 260,700 | 0 | 0 | 0 | For |
| COLDSTREAM CAPITAL MANAGEMENT INC | 250,001 | 0 | 0 | 0 | For |
| Cerity Partners LLC | 248,950 | 0 | 0 | 0 | For |
| MERCER GLOBAL ADVISORS INC /ADV | 185,646 | 0 | 0 | 0 | For |
| JOHNSON INVESTMENT COUNSEL INC | 150,420 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 124,438 | 0 | 0 | 0 | For |
| EP Wealth Advisors, LLC | 68,000 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 65,000 | 0 | 0 | 0 | For |
| Kovitz Investment Group Partners, LLC | 63,745 | 0 | 0 | 0 | For |
| Northeast Financial Group, Inc. | 62,100 | 0 | 0 | 0 | For |
| Northern Trust | 59,013 | 0 | 0 | 0 | For |
| Perkins Coie Trust Co | 47,500 | 0 | 0 | 0 | For |
| Belpointe Asset Management LLC | 38,950 | 0 | 0 | 0 | For |
| CHEVY CHASE TRUST Co | 37,854 | 0 | 0 | 0 | For |
| RBC Dominion Securities Inc. | 33,700 | 0 | 0 | 0 | For |
| TRUIST FINANCIAL CORP | 33,485 | 0 | 0 | 0 | For |
| UNITED CAPITAL FINANCIAL ADVISORS, LLC | 31,681 | 0 | 0 | 0 | For |
| ENVESTNET ASSET MANAGEMENT INC | 30,377 | 0 | 0 | 0 | For |
| Beacon Pointe Advisors, LLC | 28,290 | 0 | 0 | 0 | For |
| Empower | 12,460 | 12,460 | 0 | 0 | Mixed |
Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: ADVISORY VOTE TO RATIFY NAMED EXECUTIVE OFFICERS' COMPENSATION
NORTHWEST BIOTHERAPEUTICS INC.’s own tally for this item (“3. Ratification Of The Same Option Awards That Were Made In 2020 To The Named Executive Officers And For Which The Stockholders Already Voted In Favor In An Advisory Vote At The 2021 Annual Meeting And In A Ratification ”): 667,076,388 for, 89,877,155 against, per its Form 8-K filed July 3, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 2 asset managers below reported 1,205 for, 6,000 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Berkeley Capital Partners, LLC | 0 | 6,000 | 0 | 0 | Against |
| TD ASSET MANAGEMENT INC | 1,205 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 1,208,177,416 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Badgley Phelps Wealth Managers, LLC | 0.05% |
| 2 | BNY Mellon | 0.05% |
| 3 | HighTower Advisors, LLC | 0.03% |
| 4 | Corient Private Wealth LLC | 0.02% |
| 5 | OPPENHEIMER & CO INC | 0.02% |
| 6 | Moloney Securities Asset Management, LLC | 0.02% |
| 7 | COLDSTREAM CAPITAL MANAGEMENT INC | 0.02% |
| 8 | Cerity Partners LLC | 0.02% |
| 9 | MERCER GLOBAL ADVISORS INC /ADV | 0.02% |
| 10 | JOHNSON INVESTMENT COUNSEL INC | 0.01% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Marnix L. Bosch, Ph.D., M.B.A. | 2.92% | DEF14A |
| Linda F. Powers | 2.43% | DEF14A |
| Dr. Navid Malik | 1.99% | DEF14A |
| Pat Sarma | 1.04% | DEF14A |
| J. Cofer Black | 0.54% | DEF14A |
| Alton L. Boynton, Ph.D. | 0.25% | DEF14A |
| Leslie J. Goldman | 0.01% | DEF14A |
Percentages above are of 1,208,177,416 shares outstanding, as reported by NORTHWEST BIOTHERAPEUTICS INC. on its Form 10-Q dated May 6, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from NORTHWEST BIOTHERAPEUTICS INC.’s 10-Q dated May 6, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
NORTHWEST BIOTHERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2025-2026.
proxyvotesnow.com, “NORTHWEST BIOTHERAPEUTICS (NWBO) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/northwest-biotherapeutics-inc/2024 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.